Geographical Variation in Breast Cancer Outcomes

Baade, Peter D.

doi:10.3390/ijerph14050523

Cited by 22 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the most common cancers and the No.1 killer among women malignancies in the world, breast cancer brings women severe hurts physically and psychologically [15][16][17]. For the past ten years, the treatment of BC has many problems, such as drug resistance and poor prognosis, which reveals BC still is a high-risk disease.…”

Section: Discussionmentioning

confidence: 99%

Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

Chen

Cao

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Breast cancer (BC) is a malignancy with high incidence among women in the world. This study aims to screen key genes and potential prognostic biomarkers for BC using bioinformatics analysis. Total 58 normal tissues and 203 cancer tissues were collected from three Gene Expression Omnibus (GEO) gene expression profiles, and then the differential expressed genes (DEGs) were identified. Subsequently, the Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway were analyzed to investigate the biological function of DEGs. Additionally, hub genes were screened by constructing a protein-protein interaction (PPI) network. Then, we explored the prognostic value and molecular mechanism of these hub genes using Kaplan-Meier (KM) curve and Gene Set Enrichment Analysis (GSEA). As a result, 42 upregulated and 82 down-regulated DEGs were screened out from GEO datasets. The DEGs were mainly related to cell cycles and cell proliferation by GO and KEGG pathway analysis. Furthermore, 12 hub genes (FN1,

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

Chen

Cao

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Breast cancer, one of the most common malignancies among women in China and even in the world at present, has become the leading killer threatening the health of women, which accounts for about 20% of malignant tumors among women [ 1 ]. With the deepening of studies, it is found by researchers that patients with breast cancer are younger in recent years, and the incidence rate of breast cancer is increasing year by year with enhanced social survival and work stress [ 2 , 3 ]. Reports of the World Health Organization have stated that about 1.5 million people suffer from breast cancer every year worldwide, and about 500,000 patients with breast cancer die.…”

Section: Introductionmentioning

confidence: 99%

Effects of Ulinastatin on Proliferation and Apoptosis of Breast Cancer Cells by Inhibiting the ERK Signaling Pathway

Xing

Wang

Liu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Purpose. To explore the effects of ulinastatin on the proliferation and apoptosis of breast cancer cells and the relevant mechanism of action. Methods. Breast cancer cells (MCF-7) were cultured and randomly divided into three groups, namely, control group, ulinastatin group, and ulinastatin+extracellular-regulated protein kinase (ERK) inhibitor group. Then, the Cell Counting Kit-8 (CCK-8) assay was carried out to detect the effect of ulinastatin on the viability of breast cancer cells. The effects of ulinastatin on the proliferation and apoptosis of breast cancer cells were determined via EdU staining and Hoechst 33258 staining assays, respectively. The messenger ribonucleic acid (mRNA) and protein expression levels of ERK and forkhead box O3 (FOXO3) in breast cancer cells were measured through reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Results. In comparison with the control group, the ulinastatin group displayed decreased viability of breast cancer cells, a decreased positive rate of 5-ethynyl-2 ′ -deoxyuridine (EdU) staining, an increased positive rate of Hoechst 33258 staining, and reduced mRNA and protein levels of ERK and FOXO3 in breast cancer cells. Compared with those in the ulinastatin group, the viability of breast cancer cells was lowered, the positive rate of EdU staining was reduced, the positive rate of Hoechst 33258 staining was raised, and the mRNA and protein levels of ERK and FOXO3 in breast cancer cells clearly declined in the ulinastatin+ERK inhibitor group. Conclusion. Ulinastatin inhibits the proliferation and promotes the apoptosis of breast cancer cells. The possible mechanism of action is associated with the suppression of the ERK signaling pathway.

show abstract

“…7,19 Beside alterations in certain genes, several factors such as family history, marital status and lifestyle play significant roles in the cancer development. 20,21 Most importantly, mutations in tumour suppressor genes such as BRCA1 and BRCA2 play a notable part in the progression to breast cancer. BRCA1 is a nuclear phosphoprotein encoding tumour suppressor gene that play a part in conserving genomic stability.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of BRCA1/BRCA2 frequent mutations in the Pakistani breast cancer patients.

Shabana

Liaqat

Maqsood

et al. 2020

TPMJ

View full text Add to dashboard Cite

Objectives: Breast cancer is the most common cause of death in women. 20% of breast cancer cases are due to the variations in the BRCA1/BRCA2 genes. Various variants of BRCA1/2 genes have been reported worldwide, which cause breast cancer by forming truncated proteins. In the current study, we aimed to find out the prevalence of mutations 1294DEL40, E1250X and 5382insC (BRCA1) and 2157DELG (BRCA2) in a case control cohort of Pakistani origin. Study Design: Case Control Study. Setting: Microbiology and Molecular Genetics University of Punjab, Lahore. Period: December 2017 to June 2018. Material & Methods: Blood samples from 80 female breast cancer patients and 80 healthy females were taken. DNA was isolated from blood by manual method and genotyping was done by PCR-RFLP. Results: We found that for the 2157DELG mutation of the BRCA2 gene, homozygous mutant phenotype is present only in the cases at a frequency of 25% while the BRCA1 gene mutations were less common i.e., the E1250X mutation showed 6.6% prevalence in patients, and the 1294del40 and 5382insC mutations were absent in the current cohort. Conclusion: Despite of sample size limitation, this study provides information about the prevalence of some common mutations. In addition, clinical risk factors were also noted which are essential in risk assessment. We foresee that targeting of specific genetic variants restricted to a particular ethnic group would be more effective in the future therapeutic approaches for the prevention and cure of breast cancer.

show abstract

Geographical Variation in Breast Cancer Outcomes

Cited by 22 publications

References 17 publications

Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

Effects of Ulinastatin on Proliferation and Apoptosis of Breast Cancer Cells by Inhibiting the ERK Signaling Pathway

Prevalence of BRCA1/BRCA2 frequent mutations in the Pakistani breast cancer patients.

Contact Info

Product

Resources

About